Raymond James & Associates Nurix Therapeutics, Inc. Transaction History

Raymond James & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	BUY	$4.25 - $10.71 $12,826 - $32,322	3,018 Added 3.08%	101,006 $1.04 Million
Q3 2023 Oct 24, 2023	BUY	$7.86 - $10.08 $43,599 - $55,913	5,547 Added 6.0%	97,988 $770,000
Q2 2023 Jul 25, 2023	BUY	$8.7 - $13.28 $212,540 - $324,430	24,430 Added 35.92%	92,441 $923,000
Q1 2023 Apr 14, 2023	BUY	$8.56 - $13.26 $145,348 - $225,154	16,980 Added 33.27%	68,011 $603,000
Q4 2022 Feb 08, 2023	SELL	$9.86 - $14.59 $473 - $700	-48 Reduced 0.09%	51,031 $560,000
Q3 2022 Oct 25, 2022	BUY	$12.33 - $19.81 $120,834 - $194,138	9,800 Added 23.74%	51,079 $666,000
Q2 2022 Aug 12, 2022	BUY	$7.88 - $14.82 $325,278 - $611,754	41,279 New	41,279 $523,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.